TMS Co., Ltd. ( (JP:4891) ) has provided an announcement.
TMS Co., Ltd. has entered into a joint research agreement with Tokushima University to study a novel soluble Epoxide Hydrolase inhibitor. This collaboration is part of TMS’s strategy to leverage academic partnerships for pharmaceutical advancements, although it will not impact the company’s financial results for the current fiscal year.
More about TMS Co., Ltd.
TMS Co., Ltd. is a clinical-stage biopharmaceutical company focused on discovering and developing transformative medicines for serious diseases with high unmet medical needs. Their pipeline includes small molecule compounds called SMTPs, with programs targeting acute ischemic stroke, resistant hypertension, acute kidney injury, and spinal cord injury. TMS collaborates with academic institutions in Japan to bridge academic discoveries with the global pharmaceutical market.
YTD Price Performance: 0.46%
Average Trading Volume: 1,716,612
Technical Sentiment Consensus Rating: Hold
Current Market Cap: Yen8.83B
See more insights into 4891 stock on TipRanks’ Stock Analysis page.